Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06961747 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women
A Phase 1 study of Healthy Participants, sponsored by UCB Biopharma SRL.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 2
- Study locations
NCT06961747: Recruiting Phase 1 study of Healthy Participants, sponsored by UCB Biopharma SRL.
NCT06961747 is a Phase 1 study of Healthy Participants that is actively recruiting participants, run by UCB Biopharma SRL. The registered enrollment target is 15 participants, below the 66-participant average among 119 other Healthy Participants trials with a reported enrollment target (77% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06961747, a Phase 1 study of Healthy Participants, is actively recruiting participants, sponsored by UCB Biopharma SRL.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess the steady state (SS) concentrations of zilucoplan (ZLP) and its major metabolites in mature breast milk of healthy study participants following injection of repeated once-daily doses of ZLP.
Primary Outcome
Maternal breast milk samples will be collected for measurement of zilucoplan and its major metabolites.
Conditions Studied
Interventions
- DRUG Zilucoplan
Study Locations (2)
Texas
- UP0137 2 - San Antonio
Utah
- UP0137 1 - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-07-09 |
| Est. Completion | 2026-07-22 |
| Phase | Phase 1 |
What NCT06961747 shows while recruiting
NCT06961747 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 66-participant average among 119 other Healthy Participants trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 1 intervention - of which Zilucoplan is the first listed.
NCT06961747 reports a single indexed study location in Texas, Utah.
Frequently Asked Questions
What is clinical trial NCT06961747 about?
NCT06961747 is a clinical study titled "A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women". The purpose of this study is to assess the steady state (SS) concentrations of zilucoplan (ZLP) and its major metabolites in mature breast milk of healthy study participants following injection of repeated once-daily doses of ZLP.
What is the current status of trial NCT06961747?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2025-07-09. Estimated completion is 2026-07-22.
What conditions does trial NCT06961747 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT06961747?
The interventions under investigation include: Zilucoplan (DRUG).
Who is sponsoring clinical trial NCT06961747?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06961747 being conducted?
This trial has 2 study locations across Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06961747's enrollment target sits among peer trials
15 105th of 119 higher than 14 of 119 other Healthy Participants trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI